[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 143
1. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol; 2006 Jan 10;24(2):228-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
  • MATERIALS AND METHODS: VEGF-C, VEGF-D, and VEGFR-3 were analyzed in 91 R(0)-resected primary gastric adenocarcinomas, corresponding noncancerous gastric mucosa, and lymph node metastases employing immunohistochemistry and/or in situ hybridization.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / mortality. Stomach Neoplasms / chemistry. Stomach Neoplasms / mortality. Vascular Endothelial Growth Factor D / analysis. Vascular Endothelial Growth Factor Receptor-3 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


2. Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL: Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology; 2005 Dec;129(6):2058-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation.
  • METHODS: We studied a case of early onset gastric adenocarcinoma after nonmyeloablative hematopoietic stem cell transplantation for myeloma in a 56-year-old man.
  • RESULTS: The development of gastric adenocarcinoma was preceded by severe graft-versus-host disease (GVHD) necessitating strong immunosuppression, which resulted in an intense reactivation of EBV infection.
  • Three sequential gastric biopsy examinations performed at 100, 130, and 150 days after hematopoietic stem cell transplantation showed gastritis, dysplasia, and adenocarcinoma, respectively.
  • In situ hybridization for EBV-encoded early small RNA showed absence of EBV in the gastritis specimen, but the presence of EBV in the dysplastic and carcinoma specimens.
  • [MeSH-major] Adenocarcinoma / etiology. Epstein-Barr Virus Infections / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Herpesvirus 4, Human. Neoplasms, Second Primary. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344071.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


3. Yannopoulos P, Theodoridis P, Manes K: Esophagectomy without thoracotomy: 25 years of experience over 750 patients. Langenbecks Arch Surg; 2009 Jul;394(4):611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stomach was our esophageal substitute of first choice with the colon and jejunum being acceptable alternatives in patients with prior gastric surgery and those necessitating synchronous gastrectomy for cancer invasion.
  • A gastric tube was used as an esophageal substitute in 624 patients (83.2%), the whole stomach in 70 (9.4%), the colon in 43 (5.73%), and a jejunal loop in 13 (1.73%).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Feb;25(2):196-203 [11338022.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):162-7 [11918882.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):197-209 [12838490.001]
  • [Cites] Dis Esophagus. 2003;16(3):243-5 [14641318.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):627-31; discussion 631-3 [15197089.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1170-6; discussion 1170-6 [15464465.001]
  • [Cites] Br J Surg. 1975 Aug;62(8):601-4 [1174797.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Nov;76(5):643-54 [703369.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):419-23; discussion 424 [2635923.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):366-9 [2025191.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):157-63 [7967604.001]
  • [Cites] Chest Surg Clin N Am. 1997 Aug;7(3):601-10; discussion 611-2 [9246405.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):593-610 [15927654.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • (PMID = 19350267.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2687514
  •  go-up   go-down


Advertisement
4. Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarão MF, Calcagno DQ, Khayat AS, Assumpção PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR: Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet; 2009 Nov;195(1):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we describe the establishment and cytogenetic characterization of three new gastric cancer cell lines obtained from primary gastric adenocarcinoma (ACP02 and ACP03) and cancerous ascitic fluid (AGP01) of individuals from northern Brazil.
  • Chromosome 8 aneusomy was confirmed by fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Line, Tumor. Stomach Neoplasms / genetics


5. Zhang L, Sanderson SO, Lloyd RV, Smyrk TC: Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
  • Morphologic, clinical, and genetic evidence suggests that pancreatic intraepithelial neoplasia (PanIN) is a precursor to ductal adenocarcinoma.
  • The presence of PanIN in heterotopic pancreas from patients with ductal adenocarcinoma supports the progression model.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Choristoma / pathology. Duodenal Diseases / pathology. Pancreas. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology


6. Ribeiro-Mourão F, Pimentel-Nunes P, Dinis-Ribeiro M: Endoscopic submucosal dissection for gastric lesions: results of an European inquiry. Endoscopy; 2010 Oct;42(10):814-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most cases were non-invasive high-grade intraepithelial neoplasia (44 %) or adenocarcinoma (36 %).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Dissection / utilization. Gastric Mucosa / surgery. Stomach Neoplasms / surgery


7. Stănciulea O, Preda C, Herlea V, Popa M, Ulmeanu D, Vasilescu C: [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis]. Chirurgia (Bucur); 2007 Mar-Apr;102(2):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological exam revealed duodenal G2 adenocarcinoma pT3N0, and gastric hyperplastic polyps with no signs of dysplasia.
  • The patient underwent transverse colectomy (the histopathological exam--in situ carcinoma).
  • In 2005 was noted a pulmonary nodule, located in the postero-apical segment of upper left lobe, for which left superior lobe resection was performed (the histopathological exam: metastatic adenocarcinoma).
  • [MeSH-minor] Ampulla of Vater. Humans. Male. Middle Aged. Stomach Neoplasms / surgery. Treatment Outcome


8. Zhang J, Fu YC, Kang CS, Zhang QY, Wang T, Zhang J: [Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]. Zhonghua Yi Xue Za Zhi; 2009 Aug 25;89(32):2292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth].
  • OBJECTIVE: To construct a short hairpin RNA (shRNA) adenovirus vector targeting Akt1 (protein kinase B1, PKB1/Akt1) and cyclooxygenase-2 (COX-2) and study its effects on the growth of SGC-7901 human gastric adenocarcinoma cell.
  • The proliferative activity of tumor cell was evaluated by MTT assay and flow cytometry in vitro. rAd5-HK and rAd5-A + C were injected into the established subcutaneous SGC-7901 gastric adenocarcinoma in nude mice.
  • During the observation period of 21 days, tumor volume was measured every 3 days to further observe the anti-tumor effects of rAd5-A + C on SGC-7901 cell and cell situ apoptosis was detected by TUNEL assay.
  • CONCLUSION: Adenovirus-mediated Akt1 and COX-2 shRNA can inhibit the growth of SGC-7901 human gastric adenocarcinoma cell.
  • [MeSH-major] Cyclooxygenase 2 / genetics. RNA, Small Interfering / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095346.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


9. Papaziogas B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Paraskevas G, Argiriadou H, Atmatzidis S, Atmatzidis K: Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. Cases J; 2008;1(1):249
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report.
  • Microscopically, an endoepithelial (in situ) carcinoma of the gastric antrum was determined, which in places turned into an microinvasive endomucosal adenocarcinoma.
  • It also incidentally demonstrated heterotopic pancreatic ducts, detected within the mucosa to the muscularis propria of the same region of the stomach, in which an endoepithelial (in situ) carcinoma was evolving.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1995 May;33(5):260-4 [7610694.001]
  • [Cites] Histopathology. 1992 May;20(5):433-5 [1587493.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1289-92 [1812259.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):196-8 [2032610.001]
  • [Cites] Postgrad Med J. 1988 Oct;64(756):801-3 [3255924.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):593-9 [894461.001]
  • [Cites] Can J Surg. 1976 Sep;19(5):413-4 [974927.001]
  • [Cites] Arch Surg. 1974 Dec;109(6):762-5 [4420439.001]
  • [Cites] J Korean Med Sci. 2004 Feb;19(1):145-8 [14966359.001]
  • [Cites] Can J Surg. 2001 Dec;44(6):407 [11764870.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):549-54 [11472568.001]
  • [Cites] West J Med. 1981 Jul;135(1):57-62 [7257381.001]
  • (PMID = 18928565.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577107
  •  go-up   go-down


10. Bouché O, Penault-Llorca F: [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer; 2010 Dec;97(12):1429-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or gastro-oesophageal junction (GOJ) cancers.
  • Trastuzumab plus FP chemotherapy has become the standard treatment for patients with HER2+ non-pretreated metastatic adenocarcinoma of the stomach or GOJ cancer.
  • Equivocal IHC2+ tumours should be tested by ISH with two tools: fluorescence in situ hybridization (FISH) or bright field in situ hybridization (SISH).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Esophagogastric Junction. Receptor, ErbB-2 / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Cisplatin / administration & dosage. Cisplatin / contraindications. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Paraffin Embedding. Randomized Controlled Trials as Topic. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134821.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Zhang J, Fu YC, Kang CS, Zhang QY, Wang T, Zhang J: [Inhibitory effect of adenovirus-mediated short hairpin RNA targeting P85 and Akt1 on growth of human gastric adenocarcinoma cell]. Zhonghua Nei Ke Za Zhi; 2009 Jul;48(7):557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effect of adenovirus-mediated short hairpin RNA targeting P85 and Akt1 on growth of human gastric adenocarcinoma cell].
  • OBJECTIVE: To construct a short hairpin RNA(shRNA) adenovirus vector targeting P85 and protein kinase B1 (PKB1/Akt1) and study its effects on the growth of SGC-7901 human gastric adenocarcinoma cells.
  • The proliferative activity of tumor cells was evaluated with MTT assay and flow cytometry in vitro. rAd5-HK and rAd5-P + A mediated by adenovirus were injected into the established subcutaneous SGC-7901 gastric adenocarcinoma in nude mice.
  • During the observation period of 21 days, tumor volume was measured every 3 days to further testify the anti-tumor effect of rAd5-P + A on the SGC-7901 gastric adenocarcinoma cells and cell in situ apoptosis was detected with TUNEL assay.
  • RESULTS: The adenovirus vector rAd5-P + A was successfully constructed and it dramatically downregulated P85 and Akt1 mRNA expression in SGC-7901 gastric adenocarcinoma cells.
  • Moreover, rAd5-P + A could induce cell in situ apoptosis.
  • CONCLUSIONS: Adenovirus-mediated targeting P85 and Akt1 shRNA can inhibit the growth of SGC-7901 human gastric adenocarcinoma cells and this may provide a new strategy of combination gene therapy in gastric adenocarcinoma.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / genetics. RNA, Small Interfering. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957795.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


12. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.


13. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


14. van Dekken H, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Wink JC, van Duin M: Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer; 2008 Aug;47(8):649-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, immunohistochemistry did not show expression of CDK6 in Barrett's dysplasia and carcinoma in situ, correlating expression of CDK6 with a malignant phenotype.
  • [MeSH-major] Chromosomes, Human, Pair 7. Cyclin-Dependent Kinase 6 / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction. Gene Expression Profiling. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma. Gene Amplification. Hepatocyte Growth Factor / analysis. Hepatocyte Growth Factor / genetics. Humans. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-met. Receptors, Growth Factor / analysis. Receptors, Growth Factor / genetics


15. Herath CH, Chetty R: Epstein-Barr virus-associated lymphoepithelioma-like gastric carcinoma. Arch Pathol Lab Med; 2008 Apr;132(4):706-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoepithelioma-like gastric carcinoma is a rare neoplasm of the stomach with a better prognosis than conventional adenocarcinoma.
  • Distinctive histology and demonstration of EBV using in situ hybridization, polymerase chain reaction, or Southern blotting and immunohistochemistry for the DNA mismatch repair genes or polymerase chain reaction analysis of microsatellite loci to assess microsatellite instability helps to make the diagnosis.
  • [MeSH-major] Carcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384225.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 40
  •  go-up   go-down


16. Lima MA, Ferreira MV, Barros MA, Pardini MI, Ferrasi AC, Mota RM, Rabenhorst SH: Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas. Diagn Mol Pathol; 2008 Jun;17(2):82-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: One hundred patients of gastric carcinoma, obtained from 2 hospitals in Fortaleza, Brazil were assessed for the presence of EBV by in situ hybridization, for the expression of Bcl-2, Bax, and c-Myc (nuclear and cytoplasmic staining) proteins by immunohistochemistry techniques, and for the apoptotic index.
  • [MeSH-major] Adenocarcinoma / metabolism. Epstein-Barr Virus Infections / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Female. Gastrectomy. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382371.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Epstein-Barr virus encoded RNA 1; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Viral; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


17. Furuya T, Uchiyama T, Adachi A, Chochi Y, Oga A, Kawauchi S, Ishiglo K, Sasaki K: Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas. Oncol Rep; 2006 Jun;15(6):1491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, numerical aberrations in chromosomes 7, 11, 17, and 18 were evaluated by fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Ploidies. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685384.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


18. van Duin M, van Marion R, Watson JE, Paris PL, Lapuk A, Brown N, Oseroff VV, Albertson DG, Pinkel D, de Jong P, Nacheva EP, Dinjens W, van Dekken H, Collins C: Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry A; 2005;63(1):10-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For validation of the array DNA samples of gastroesophageal and prostate cancer cell lines, and chronic myeloid leukemia specimens were used, which were previously characterized by multicolor fluorescence in situ hybridization and conventional CGH.
  • Single copy loss and high-level amplifications were accurately detected and confirmed by bicolor fluorescence in situ hybridization experiments.
  • [MeSH-minor] Adenocarcinoma / genetics. Cardia. Chromosome Aberrations. Fixatives. Formaldehyde. Humans. In Situ Hybridization, Fluorescence. Male. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Stomach Neoplasms / genetics. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619731.001).
  • [ISSN] 1552-4922
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


19. Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D: Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res; 2009;28:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Formalin-fixed paraffin-embedded tissue from these resection specimens were assessed for EBV by in situ hybridization, the gold standard for EBV detection in tissue.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / virology. Tumor Virus Infections / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gastric Mucosa / virology. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / biosynthesis. Retrospective Studies. Risk Factors. United States. Viral Matrix Proteins / biosynthesis. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1063-71 [8214002.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):805-9 [8039108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Histopathology. 1994 Oct;25(4):323-9 [7835837.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] J Pathol. 1997 Nov;183(3):293-8 [9422984.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Med Virol. 2001 Aug;64(4):513-8 [11468737.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):612-8 [11522745.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):33-40 [14550950.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):201-11 [14639106.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):487-91 [15113855.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • (PMID = 19192297.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2642773
  •  go-up   go-down


21. Ma J, Zhang L, Ru GQ, Zhao ZS, Xu WJ: Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1680-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In situ hybridization was used to examine expression of HIF-1alpha mRNA, and immunohistochemical staining was used to examine expression of VEGF protein and CD34 in 118 specimens from patients with gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Signet Ring Cell / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Neovascularization, Pathologic / physiopathology. Stomach Neoplasms / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Middle Aged. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / physiopathology. Prognosis. RNA, Messenger / metabolism. Stomach / pathology. Stomach / physiopathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S61-75 [17259560.001]
  • [Cites] Oncology. 2002;62(2):157-66 [11914602.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1831-7 [12060624.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2002 May 25;82(10):708-11 [12133473.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 11;1578(1-3):73-83 [12393189.001]
  • [Cites] Oncology. 2003;64(1):61-73 [12457033.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Histopathology. 2005 Jan;46(1):31-6 [15656883.001]
  • [Cites] Exp Mol Pathol. 2005 Apr;78(2):123-30 [15713437.001]
  • [Cites] J Urol. 2005 May;173(5):1762-6 [15821583.001]
  • [Cites] Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug;25(8):1034-6 [16109571.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):770-4 [16424008.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jan;5(5):350-3 [16512994.001]
  • [Cites] BMC Cancer. 2006;6:26 [16438736.001]
  • [Cites] Curr Opin Hematol. 2006 May;13(3):169-74 [16567961.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 29;266(3):718-22 [10603309.001]
  • [Cites] Anat Rec. 2000 Jun 15;261(3):126-35 [10867630.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3970-6 [16810742.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5112-7 [16951228.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6123-7 [16682946.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1272-7 [16814458.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2332-5 [17164353.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):908-14 [11866451.001]
  • (PMID = 17461470.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC4146946
  •  go-up   go-down


22. Bennett VS, Bailey DM: Cholangiocarcinoma presenting as a solitary epididymal metastasis: a case report and review of the literature. Diagn Pathol; 2007;2:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other primary carcinomas that have been demonstrated to metastasize to the paratesticular region include those originating in the stomach, kidney, ileum, and colon.
  • Computed tomography of the abdomen demonstrated an obstructive stricture of the extra-hepatic bile ducts, in keeping with a cholangiocarcinoma, through which a metal stent was endoscopically inserted for symptomatic relief.Subsequent right radical orchidectomy yielded a diffusely infiltrative adenocarcinoma obliterating the epididymis, extending into the rete testis, vas deferens and spermatic cord and showing widespread vascular and perineural invasion.
  • Residual epididymal, rete, and testicular tubules showed no in situ neoplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1983;9(1):56-9 [6822245.001]
  • [Cites] Jpn J Clin Oncol. 1994 Dec;24(6):340-4 [7830340.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):198-9 [9052433.001]
  • [Cites] Int J Urol. 1998 Jan;5(1):106-7 [9535613.001]
  • [Cites] Histopathology. 2000 Oct;37(4):323-31 [11012739.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S131-45 [15502808.001]
  • [Cites] J Urol. 1989 Oct;142(4):1003-5 [2677407.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):709-14 [6204734.001]
  • (PMID = 17760973.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2000863
  •  go-up   go-down


23. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet; 2010 Aug 28;376(9742):687-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumours showed overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Esophagogastric Junction. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet. 2010 Aug 28;376(9742):659-60 [20728211.001]
  • [CommentIn] Lancet. 2010 Nov 20;376(9754):1735; author reply 1735-6 [21093641.001]
  • [CommentIn] Gastroenterology. 2011 Jan;140(1):356-8; discussion 358 [21087674.001]
  • [CommentIn] Biomark Med. 2010 Dec;4(6):793 [21174864.001]
  • [CommentIn] Nat Rev Clin Oncol. 2010 Nov;7(11):611 [21049571.001]
  • [ErratumIn] Lancet. 2010 Oct 16;376(9749):1302
  • (PMID = 20728210.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01041404
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Investigator] Parnis F; McKendrick J; Price T; Mainwaring P; Van Cutsem E; Forones N; Olivatto L; Miziara JE; Li J; Wang J; Wang Y; Zheng L; Wang L; Feng-Yi F; Shen L; Xu JM; Jiao S; Guan Z; Yu SY; Pan L; Jin Y; Tao M; Qin S; Reyes DO; Valladares R; Landaverde D; Pfeiffer P; Vestlev PM; Tanner M; Bouche O; Michel P; Jacob J; Husseini F; Metges JP; Dominguez S; Viret F; Clemens M; zum Büschenfelde CO; Moehler M; Hoefeler H; Lordick F; Toache LM; Castro-Salguero H; Prasad SV; Gangadharan VP; Advani S; Julka PK; Aprile G; Barone C; Cascinu S; Di Costanzo F; Stefania S; Hamamoto Y; Sasaki Y; Yamaguchi K; Ohtsu A; Hatake K; Satoh A; Boku N; Sawaki A; Takiuchi H; Tamura T; Baba E; Nishina T; Miyata Y; Satoh T; Omuro Y; Saito H; Bang YJ; Kang YK; Hong DS; Jeung HC; Lim HY; Chung HC; Kim JG; Kim YH; Lee K; Park S; León E; Treviño SA; Sahui TS; Rodriguez AL; Sanchez RI; Alvarez-Barreda R; de Mendoza FH; Leon-Chong J; Philco M; Sanches E; Quintela A; Sa A; Damasceno M; Coutinho C; Pinto AM; Teixeira MM; Braga S; Topuzov E; Cheporov S; Garin A; Gorbunova V; Lichinitser M; Khasanov RS; Manikhas GM; Biakhov M; Moiseenko V; Gotovkin E; Kulikov E; Lipatov O; Gladkov O; Landers G; Robertson B; Gravalos C; Queralt B; Galan MC; Gallego R; Aguilera MJ; Martin M; Fernandez-Martos C; Chao Y; Chang C; Yalcin S; Yilmaz U; Evans J; Falk S; Mansoor W; Ferry D; Thompson J; Gollins S
  •  go-up   go-down


24. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res; 2006 Jan 1;12(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Mutational Analysis. Female. Genes, ras / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics


25. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P: Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol; 2007 Dec;60(12):1358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gold standard remains in situ EBER detection, but detection of EBNA1 would be an interesting alternative.
  • The rate of EBV association with entities such as NK/T cell tumours of the nasal type is so high that absence of detection of the virus in such a lesion should cast doubt of the accuracy of the diagnosis.
  • Similarly, diagnosis of EBV-associated follicular pseudo-tumour obviously requires detection of the virus.
  • [MeSH-minor] Adenocarcinoma / virology. Hematologic Neoplasms / virology. Humans. Immunocompromised Host. Lymphoproliferative Disorders / immunology. Lymphoproliferative Disorders / virology. RNA-Binding Proteins / analysis. Ribosomal Proteins / analysis. Stomach Neoplasms / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] J Pathol. 1993 Jun;170(2):137-43 [8393922.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1044-9 [8214001.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] Virology. 1999 Apr 10;256(2):196-202 [10191184.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2745-8 [10825150.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):148-50 [11208885.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):783-90 [11259092.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):203-8 [11358725.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):721-31 [11395549.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):927-40 [11581315.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1287-92 [11583956.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1111-20 [11688570.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):482-7 [12148858.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):608-14 [12152159.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4255-60 [12377970.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] Virology. 2003 Feb 15;306(2):236-43 [12642097.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):39-45 [7805038.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1093-8 [7557942.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1300-12 [7573693.001]
  • [Cites] J Pathol. 1995 Oct;177(2):115-22 [7490676.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4531-7 [8639820.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):747-53 [8651355.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):313-24 [8772785.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Cancer Surv. 1997;30:233-48 [9547995.001]
  • [Cites] Eur Respir J. 1998 Jul;12(1):102-6 [9701422.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):59-65 [16330943.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):75-82 [16330945.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):223-9 [16434897.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2782-9 [16385574.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):250-6 [16616072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] J Pathol. 2006 Aug;209(4):430-5 [16710842.001]
  • [Cites] J Pathol. 2006 Aug;209(4):427-9 [16906594.001]
  • [Cites] J Clin Exp Hematop. 2006 Mar;46(1):1-4 [17058802.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1312-6 [17076712.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):4-14 [17064952.001]
  • [Cites] J Virol. 2007 Jun;81(11):5484-96 [17376918.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):887-95 [17509986.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):588-94 [17417777.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):44-53 [17555446.001]
  • [Cites] J Virol. 2007 Jul;81(13):7249-68 [17376908.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1077-88 [17592275.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] J Oral Pathol Med. 2004 Jan;33(1):30-6 [14675138.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Uirusu. 2003 Dec;53(2):211-6 [15071960.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):455-9 [15116326.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Can Med Assoc J. 1970 Dec 19;103(13):1362-5 [4923839.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • (PMID = 17873116.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  • [Number-of-references] 72
  • [Other-IDs] NLM/ PMC2095566
  •  go-up   go-down


26. Chong Y, Shin JJ, Cho MY, Cui Y, Kim HY, Park KH: Synchronous primary gastric mantle cell lymphoma and early gastric carcinoma: a case report. Pathol Res Pract; 2008;204(6):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged


27. Ojima H, Saito K, Yamauchi H, Yamaki E, Idetu A, Hosouchi Y, Nishida Y, Tukada K, Kato H, Kuwano H: P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res; 2006 Mar-Apr;26(2A):933-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten percent of gastric carcinomas, including lymphepithelioma-like carcinoma and adenocarcinoma, are associated with EBV infection.
  • MATERIALS AND METHODS: To clarify the relationship between p16 overexpression and EBV-associated gastric carcinomas, immunohistochemical analysis of p16 and detection of EBV by in situ hybridization were performed on 238 formalin-fixed and paraffin-embedded samples of gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] Female. Genes, p16 / physiology. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619489.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


28. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • The HPV status of the endocervical adenocarcinomas was determined by in situ hybridization and polymerase chain reaction (when in situ hybridization was negative).
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction


29. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • CONCLUSIONS: The progression of early stage cardiac cancer to advanced cancer is a very slow and long process, which is very helpful for early diagnosis and choice of therapeutic timing.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol; 2010 Dec;41(12):1742-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / enzymology. Enzyme Inhibitors / pharmacology. Ribonucleoside Diphosphate Reductase / antagonists & inhibitors. Ribonucleoside Diphosphate Reductase / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Epstein-Barr Virus Infections. Female. Gastric Mucosa. Gene Silencing. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. RNA, Small Interfering / genetics. Tissue Array Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20825972.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / RNA, Small Interfering; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase
  •  go-up   go-down


31. Zheng LD, Yang XP, Pan HX, Nie X, He J, Lv Q, Tong QS: Gastric carcinoma with osteoclast-like giant cells: a case report and review of the literature. J Zhejiang Univ Sci B; 2009 Mar;10(3):237-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biopsy and pathological findings indicated a gastric adenocarcinoma with OGCs, which were present in both the tumor and the metastatic lymph nodes.
  • In situ hybridization for Epstein-Barr virus showed no nuclear positivity in either adenocarcinoma or OGCs.
  • [MeSH-major] Giant Cells / pathology. Osteoclasts / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. In Situ Hybridization. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] Diagn Cytopathol. 2007 Sep;35(9):555-9 [17703447.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Ultrastruct Pathol. 1996 Jan-Feb;20(1):89-99 [8789215.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Ann Diagn Pathol. 1998 Aug;2(4):229-40 [9845743.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Am J Dermatopathol. 2005 Apr;27(2):126-9 [15798437.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Histopathology. 2005 Sep;47(3):331-3 [16115241.001]
  • [Cites] J Gastroenterol. 2006 Jan;41(1):83-7 [16501862.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):369-72 [16613333.001]
  • [Cites] Pancreas. 2006 Oct;33(3):304-10 [17003654.001]
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):111-2 [17230568.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • (PMID = 19283880.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 16
  • [Other-IDs] NLM/ PMC2650035
  •  go-up   go-down


32. Zhao CH, Li QF: Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells. World J Gastroenterol; 2005 Aug 14;11(30):4628-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells.
  • AIM: To find and identify specific nuclear matrix proteins associated with proliferation and differentiation of carcinoma cells, which will be potential markers for cancer diagnosis and targets in cancer therapy.
  • Spots of nuclear matrix proteins differentially expressed were excised and subjected to in situ digestion with trypsin.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Neoplasm Proteins / metabolism. Nuclear Matrix-Associated Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Matrix-Associated Proteins
  • [Other-IDs] NLM/ PMC4615401
  •  go-up   go-down


33. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer; 2008;8:363
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
  • METHODS: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / genetics
  • [MeSH-minor] China. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 7. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1162-7 [17487844.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):137-45 [11850542.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Leukemia. 2003 Mar;17(3):532-40 [12646941.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):233-9 [12925985.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):2087-90 [2564806.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):533-42 [8630962.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):448-53 [16297090.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1798-802 [16794079.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):579-602 [17100565.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] J Thorac Oncol. 2007 May;2(5):414-22 [17473657.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:53-77 [11264450.001]
  • (PMID = 19061514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2613415
  •  go-up   go-down


34. Wang YZ, Cao YQ, Wu JN, Chen M, Cha XY: Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol; 2005 Jan 7;11(1):46-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then examined the expression of NOS, p53, PCNA in 85 samples of human gastric cancer was examined by immunohistochemistry, and NOS mRNA expression in 85 gastric cancer tissue specimens by in situ hybridization.
  • In situ hybridization analysis showed that iNOS mRNA expression was significantly stronger than eNOS mRNA expression in gastric cancer tissue (chi(2) = 10.23, P<0.01).
  • The expression of neuronal nitric oxide synthase (nNOS) was not examined by immunohistochemistry and in situ hybridization in gastric cancer specimens and normal gastric mucosa.
  • [MeSH-major] Adenocarcinoma / physiopathology. Nitric Oxide Synthase / genetics. Proliferating Cell Nuclear Antigen / metabolism. Stomach Neoplasms / physiopathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Male. Middle Aged. Nitric Oxide Synthase Type II

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609395.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4205382
  •  go-up   go-down


35. Vieth M, Stolte M: Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol; 2005 Dec;19(6):857-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucosal oesophageal carcinoma (squamous cell carcinoma and adenocarcinoma) can be subdivided into m1-m3 and m1-m4.
  • Distinction of high-grade intraepithelial neoplasia and mucosal carcinoma is without clinical relevance since the diagnosis of high-grade intraepithelial neoplasia should always first lead to a (diagnostic) endoscopic resection.
  • The final histological diagnosis could then be made on the resection specimen.
  • Diagnosis of low-grade intraepithelial neoplasia is often confused with regenerative changes.
  • [MeSH-major] Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma / pathology. Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Early Diagnosis. Humans. Neoplasm Invasiveness / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338646.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


36. Guimarães AC, Lima EM, Khayat AS, Girão Faria MH, Barem Rabenhorst SH, Pitombeira MV, Assumpção PP, de Oliveira Bahia M, Lima de Lima PD, de Arruda Cardoso Smith M, Burbano RR: Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet; 2007 Nov;179(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma.
  • Fluorescence in situ hybridization analysis with centromeric DNA probes, immunohistochemical staining, and methylation-specific polymerase chain reaction assays were performed in 15 gastric adenocarcinomas samples from individuals from northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Genes, p16. Promoter Regions, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 9. Chromosomes, Human, X. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981214.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


37. Wang LL, Yao GY, Zhang BY, Zhang XM, Zhao M: [Expression and significance of CD147 and E-cadherin in human gastric carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of CD147 and E-cadherin in gastric cancer tissue chip (TC) was detected by in situ hybridization (ISH) and immunohistochemistry in 220 cases of gastric carcinoma and 31 cases with normal gastric mucosa.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, CD147 / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / metabolism. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


38. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology; 2009 Sep;137(3):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a meta-analysis of 70 studies including 15,952 cases of gastric cancer assessed by in situ hybridization for EBV-encoded small RNA.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma / virology. Cardia / virology. Epstein-Barr Virus Infections / complications. Female. Gastric Stump. Humans. Male. Pyloric Antrum / virology. Sex Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):379-85 [16270524.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):547-53 [16471317.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1842-8 [16609989.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1270-1 [16980313.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):354-63 [10989635.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):702-4 [11875729.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2008-9 [12242430.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] J Pathol. 2003 Apr;199(4):447-52 [12635135.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):478-80 [12683879.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):641-51 [12861059.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] IARC Sci Publ. 1978;(20):167-89 [215514.001]
  • [Cites] Arch Surg. 1982 Mar;117(3):294-7 [7065870.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5455-9 [8390666.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1158-63 [7943537.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):174-81 [8607441.001]
  • [Cites] Histopathology. 1996 Feb;28(2):121-7 [8834519.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Jpn J Cancer Res. 1997 Mar;88(3):262-6 [9140110.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):360-7 [9211523.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:47-373 [9612712.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):15-23 [9659515.001]
  • [Cites] Pathol Res Pract. 1998;194(10):705-11 [9820867.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):662-6 [9930069.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1582-6 [10364028.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1214-9 [10370694.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15730-5 [15498875.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gut. 2007 Dec;56(12):1671-7 [17627962.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):884-91 [18240345.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):195-201 [18271915.001]
  • [Cites] Aging Clin Exp Res. 2008 Apr;20(2):91-102 [18431075.001]
  • [Cites] Hepatogastroenterology. 2008 Jan-Feb;55(81):41-5 [18507075.001]
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4347-51 [18666324.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1158-60 [18832388.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):570-7 [16007390.001]
  • [ErratumIn] Gastroenterology. 2011 Mar;140(3):1109
  • (PMID = 19445939.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS424076; NLM/ PMC3513767
  •  go-up   go-down


39. Ma XL, Sun HJ, Wang YS, Huang SH, Xie JW, Zhang HW: Study of Sonic hedgehog signaling pathway related molecules in gastric carcinoma. World J Gastroenterol; 2006 Jul 7;12(25):3965-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of Shh in 56 gastric specimens including non-cancerous gastric tissues, gastric adenocarcinoma, gastric squamous cell carcinoma was detected by RT-PCR, in situ hybridization and immunohistochemistry.
  • Expression of Gli1 was observed by in situ hybridization.
  • RESULTS: The positive rate of Shh and Gli1 expression was 0.0%, 0.0% in non-cancerous gastric tissues while it was 66.7%, 57.8% respectively in gastric adenocarcinoma, and 100%, 100% respectively in gastric squamous cell carcinoma.
  • Elevated expression of Shh and Gli1 in gastric tubular adenocarcinoma was associated with poorly differentiated tumors while the expression was absent in gastric mucinous adenocarcinoma.
  • CONCLUSION: The elevated expression of Shh and Gli1 in gastric adenocarcinoma and gastric squamous cell carcinoma shows the involvement of activated Shh signaling in the cellular proliferation of gastric carcinogenesis.
  • It suggests Shh signaling gene may be a new and good target gene for gastric tumor diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Hedgehog Proteins. Humans. RNA, Messenger / metabolism. Signal Transduction. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(12):2763-72 [10821773.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):99-104 [16112412.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):172-80 [11175816.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Neurosci. 2002 Feb;5(2):103-10 [11788837.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Gut. 2002 Nov;51(5):628-33 [12377798.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1829-37 [14691301.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):58-61 [9731532.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(23):9055-67 [11074003.001]
  • (PMID = 16810741.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC4087703
  •  go-up   go-down


40. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4069-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.
  • MATERIALS AND METHODS: Dual-color fluorescence in situ hybridization (FISH) for the C-MYC gene and chromosome 8 centromere was performed in 11 gastric adenocarcinomas.
  • CONCLUSION: Chromosome 8 can be used as a marker in the diagnosis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Alleles. Brazil. Gene Amplification. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Lymphocytes / ultrastructure. Male. Middle Aged. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jan-Feb;26(1a):445
  • (PMID = 16309200.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


41. Anwar M, Koriyama C, Naveed IA, Hamid S, Ahmad M, Itoh T, Minakami Y, Eizuru Y, Akiba S: Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan. J Exp Clin Cancer Res; 2005 Sep;24(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan.
  • To examine the potential role of Epstein-Barr virus (EBV) in the carcinogenesis of upper gastrointestinal tract, we conducted an in situ hybridization assay for EBV-encoded small RNA (EBER) expression in the tumors of 56 oral and 50 esophageal squamous cell carcinoma (SCC) cases, and 52 stomach adenocarcinoma cases diagnosed in the King Edward Medical College and Allama Iqbal Medical College Lahore, Pakistan between 1996-2002.
  • Only one out of the 52 gastric adenocarcinoma cases (1.9%) was positive for EBER expression, and this frequency was relatively low as compared to cases reported worldwide.
  • The case was a 42 year-old male patient and histologically classified as moderately differentiated tubular adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Gastrointestinal Neoplasms / virology. Herpesvirus 4, Human / isolation & purification
  • [MeSH-minor] Adult. Base Sequence. DNA Probes. Female. Humans. In Situ Hybridization. Male. Middle Aged. Pakistan

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270524.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


42. Liu YJ, Yan PS, Li J, Jia JF: Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol; 2005 Nov 14;11(42):6601-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relationship between the expression levels of nm23 mRNA, CD44s, and CD44v6, and oncogenesis, development and metastasis of human gastric adenocarcinoma, colorectal adenocarcinoma, intraductal carcinoma of breast, and lung cancer.
  • METHODS: Using tissue microarray by immuhistochemical (IHC) staining and in situ hybridization (ISH), we examined the expression levels of nm23 mRNA, CD44s, and CD44v6 in 62 specimens of human gastric adenocarcinoma and 62 specimens of colorectal adenocarcinoma; the expression of CD44s and CD44v6 in 120 specimens of intraductal carcinoma of breast and 20 specimens of normal breast tissue; the expression of nm23 mRNA in 72 specimens of human lung cancer and 23 specimens of normal tissue adjacent to cancer.
  • RESULTS: The expression of nm23 mRNA in the tissues of gastric and colorectal adenocarcinoma was not significantly different from that in the normal tissues adjacent to cancer (P>0.05), and was not associated with the invasion of tumor and the pathology grade of adenocarcinoma (P>0.05).
  • However, the expression of nm23 mRNA was correlated negatively to the lymph node metastasis of gastric and colorectal adenocarcinoma (r = -0.49, P<0.01; r = -4.93, P<0.01).
  • The expression of CD44s in the tissues of gastric and colorectal adenocarcinoma was significantly different from that in the normal tissues adjacent to cancer (P<0.05; P<0.01).
  • CD44v6 was expressed in the tissues of gastric and colorectal adenocarcinoma only, the expression of CD44v6 was significantly associated with the lymph node metastasis, invasion and pathological grade of the tumor (r = 0.47, P<0.01; r = 5.04, P<0.01).
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. NM23 Nucleoside Diphosphate Kinases. Neoplasm Metastasis. Nucleoside-Diphosphate Kinase. Protein Array Analysis. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425351.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC4355751
  •  go-up   go-down


43. Schiffman SC, Li Y, Dryden G, Li X, Martin RC: Positive correlation of image analysis by mini-endoscopy with micro-PET scan and histology in rats after esophagoduodenal anastomosis. Surg Endosc; 2010 Nov;24(11):2835-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies we have used micro-PET scan to analyze the esophageal adenocarcinoma (EAC) transformation in an intact rat model of esophagoduodenal anastomosis (EDA), in which intestinal metaplasia and EAC were reproduced successfully.
  • RESULTS: The endoscope provided visualization of the entire esophageal tract and upper stomach, with the smallest detectable lesion being 0.5 mm in diameter.
  • CONCLUSIONS: The new mini-endoscope constitutes a practical and reliable tool for diagnosis and regular follow-up of the esophagus in rats.
  • [MeSH-minor] Anastomosis, Surgical. Animals. Apoptosis. Cell Proliferation. Esophagoscopes. Fluorodeoxyglucose F18. In Situ Nick-End Labeling. Miniaturization. Radiopharmaceuticals. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 2007;20(5):372-8 [17760649.001]
  • [Cites] Gastroenterology. 1970 Feb;58(2):163-74 [5413015.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5176-82 [17785574.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):527-32 [16614962.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Appl Spectrosc. 2007 Jun;61(6):579-84 [17650367.001]
  • [Cites] J Surg Res. 2000 Feb;88(2):120-4 [10644476.001]
  • [Cites] N Engl J Med. 1999 Nov 4;341(19):1439 [10547407.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Dis Esophagus. 2009;22(4):323-30 [19473210.001]
  • [Cites] J Surg Res. 2006 Oct;135(2):337-44 [16926029.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):107-13 [15921698.001]
  • [Cites] Curr Opin Gastroenterol. 1999 Jul;15(4):352-8 [17023971.001]
  • [Cites] Cancer Invest. 2008 Apr-May;26(3):278-85 [18317969.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2045-55 [17473952.001]
  • (PMID = 20440518.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA127801-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Geng M, Yin YC, Cao YC, Fu ZJ, Wang XY, Tai YH: [Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA]. Zhonghua Zhong Liu Za Zhi; 2007 Nov;29(11):838-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of hTERT mRNA was detected by in situ hybridization (ISH).
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Stomach Neoplasms / pathology. Telomerase / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Cisplatin / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Fluorouracil / pharmacology. Humans. Male. Middle Aged. Mitomycin / pharmacology. Paclitaxel / pharmacology. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396642.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicate that the hedgehog pathway activation occurs in the stomach and other gastrointestinal cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Hedgehog Proteins. Humans. In Situ Hybridization. Male. Neoplasm Staging. Oncogene Proteins / genetics. Receptors, Cell Surface / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


46. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpção PP, Faria MH, Rabenhorst SH, Ferreira MV, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol; 2006 Oct 14;12(38):6207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.
  • Immunostaining for C-MYC and dual-color fluorescence in situ hybridization (FISH) for C-MYC gene and chromosome 8 centromere were performed.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aneuploidy. Brazil. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):61-4 [9809036.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):140-8 [10409442.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):157-62 [10409444.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Braz J Med Biol Res. 2004 Dec;37(12):1831-8 [15558189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14(5):526-30 [10576148.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):97-103 [10704677.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Histopathology. 2001 Feb;38(2):111-9 [11207824.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):403-6 [11819799.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):23-7 [12072199.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):66-9 [12550762.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):5-11 [12588304.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):E3 [12671026.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1759-62 [15188501.001]
  • [Cites] Nature. 1983 Nov 10-16;306(5939):194-6 [6646201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834-8 [3014513.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Recent Results Cancer Res. 1994;136:179-202 [7863095.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):226-32 [9010095.001]
  • [Cites] J Pathol. 1997 Apr;181(4):381-6 [9196434.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):119-21 [9408311.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):896-903 [9462237.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Lab Invest. 1998 Sep;78(9):1143-53 [9759658.001]
  • (PMID = 17036397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088119
  •  go-up   go-down


47. Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS: Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol; 2010 Dec;66(12):1235-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pharmacokinetic data obtained from 16 gastric adenocarcinoma patients with peritoneal seeding were used.
  • CONCLUSIONS: Our results demonstrate that a small fraction of intraperitoneally administered CPT-11 was metabolized in situ to active SN-38 and that the Vss of plasma CPT-11 following IP administration in our patient cohort was lower than that estimated in previous reports following the intravenous administration of CPT-11.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Camptothecin / analogs & derivatives. Neoplasm Seeding. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):175-84 [10676997.001]
  • [Cites] Jpn J Cancer Res. 1995 Jan;86(1):111-6 [7737902.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2182-94 [11489791.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4187-91 [10628373.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1900-8 [14578322.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3293-301 [12149304.001]
  • [Cites] Ther Drug Monit. 2005 Aug;27(4):536-8 [16044114.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2747-54 [9829738.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):141-51 [7786822.001]
  • [Cites] Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11 [20213078.001]
  • [Cites] Drug Metab Dispos. 2000 Apr;28(4):423-33 [10725311.001]
  • [Cites] J Med Chem. 1994 Jan 7;37(1):40-6 [8289200.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):133-40 [7786821.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 25;795(1):25-34 [12957166.001]
  • [Cites] AAPS J. 2011 Jun;13(2):143-51 [21302010.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):165-70 [9654118.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(12 ):2188-90 [12484033.001]
  • [Cites] Clin Pharmacol Ther. 2002 Dec;72 (6):638-47 [12496745.001]
  • [Cites] Biomed Chromatogr. 2003 Dec;17 (8):493-9 [14648604.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Oct;28(11):1505-7 [11707965.001]
  • (PMID = 20827550.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


48. Baldus SE, Mönig SP, Zirbes TK, Thakran J, Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH, Dienes HP: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol; 2006 05;21(5):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we tried to elucidate its clinicopathological relevance in a series of 160 gastric and 215 colorectal carcinomas by immunohistochemical detection of Le(y) and visualization of apoptotic cells applying the in-situ-end labelling (ISEL) method, followed by semiquantitative scoring of the specimens.
  • Signet-ring cell carcinomas of the stomach exhibited a significantly stronger Le(y) expression compared to other tumor types.
  • [MeSH-major] Adenocarcinoma / immunology. Apoptosis. Carcinoma, Signet Ring Cell / immunology. Colorectal Neoplasms / immunology. Lewis Blood-Group System / analysis. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493580.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


49. Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W: Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer; 2008 Apr 15;112(8):1688-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.
  • BACKGROUND: Upper gastrointestinal adenocarcinomas are a common cause of cancer-related deaths.
  • In this study, the authors investigated the prevalence and biological significance of Aurora Kinase A (AURKA) overexpression in upper gastrointestinal adenocarcinomas.
  • METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining on tumor tissue microarrays (TMA) were used to study the expression of AURKA in upper gastrointestinal adenocarcinomas.
  • To investigate the biological and signaling impact of AURKA, the authors used multiple in vitro assays that included 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), TUNEL (terminal deoxynucleotidyl transferase-mediated nick-end labeling), cytochrome C release, flow cytometry, luciferase reporter, and Western blot analysis.
  • RESULTS: Frequent overexpression of AURKA transcript in upper gastrointestinal adenocarcinomas was detected compared with normal samples (47%; P= .001).
  • The immunohistochemical analysis of 130 tumors demonstrated moderate-to-strong immunostaining of AURKA in >50% of upper gastrointestinal adenocarcinomas.
  • By using camptothecin as a drug-induced apoptosis in vitro model, the authors demonstrated that the expression of AURKA provided protection against apoptosis to gastrointestinal cancer cells (AGS and RKO) (P= .006) and RIE-1 primary intestinal epithelial cells (P= .001).
  • The AURKA overexpression mediated an increase in phosphorylation of AKT(Ser473) with an increase in HDM2 level.
  • The shRNA-knockdown of AKT in AURKA-overexpressing cells reversed this effect and showed a significant increase in the p53 protein level, indicating a possible nexus of AURKA/AKT/p53.
  • Indeed, overexpression of AURKA led to a remarkable reduction in the transcription activity of p53, with subsequent reductions in transcript and protein levels of its downstream proapoptotic transcription targets (p21, BAX, NOXA, and PUMA).
  • CONCLUSIONS: Study results indicated that AURKA provides potent antiapoptotic properties to gastrointestinal cells by regulating levels of p53 through the AKT/HDM2 axis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Cell Res. 2006 Apr;16(4):356-66 [16617331.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):370-3 [11291073.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):483-92 [11847097.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9 [12208897.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1173-82 [12390251.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):273-91, viii [12424850.001]
  • [Cites] Med Clin North Am. 2002 Nov;86(6):1423-45, vii [12510459.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):51-62 [12559175.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):281-94 [12707311.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):267-80 [12719470.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2913-22 [12782598.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):55-62 [14702041.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28367-74 [15102863.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Science. 1997 Jan 31;275(5300):661-5 [9005851.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1595-606 [9032287.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1091-7 [15286003.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1631-9 [15547700.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5975-83 [15536123.001]
  • [Cites] Genes Cells. 2005 Jun;10(6):617-26 [15938719.001]
  • [Cites] FEBS Lett. 2005 Jun 20;579(16):3385-91 [15922328.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6583-92 [16061638.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8732-47 [16166651.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11310-6 [11115495.001]
  • (PMID = 18311783.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / CA 95103; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Enzyme Inhibitors; 0 / Luminescent Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Protein p53; 298-93-1 / thiazolyl blue; 9007-43-6 / Cytochromes c; EC 1.13.12.- / Luciferases; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS576419; NLM/ PMC4030394
  •  go-up   go-down


50. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


51. Höhler T, Rüschoff J, Ridwelski K, Moehler M: [HER2 testing and targeted therapy in advanced gastric cancer]. Onkologie; 2010;33 Suppl 4:26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients whose tumors were either scored on immunohistochemistry (IHC) as 3+ (independently of the result of fluorescence in situ hybridization (FISH)) or as IHC2+ and FISH+ were found, in a planned subgroup analysis, to have a median overall survival time of 16.0 months--versus 11.8 months when trastuzumab was not given.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Delivery Systems. Receptor, ErbB-2 / genetics. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Algorithms. Antibodies, Monoclonal, Humanized. Biopsy. Clinical Trials, Phase III as Topic. Drug Approval. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Multicenter Studies as Topic. Neoplasm Invasiveness. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Stomach / pathology. Survival Rate. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431310.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


52. Tsamandas AC, Kardamakis D, Tsiamalos P, Liava A, Tzelepi V, Vassiliou V, Petsas T, Vagenas K, Zolota V, Scopa CD: The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res; 2009 Feb;29(2):703-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thick paraffin sections (4 microm) were subjected to immunohistochemistry using anti-Bcl-2 and anti-Ki-67 antibodies and to in situ hybridization [TUNEL method-apoptotic body index (ABI)].
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Apoptosis / physiology. Ki-67 Antigen / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331225.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


53. Moon WS, Park HS, Yu KH, Jang KY, Kang MJ, Park H, Tarnawski AS: Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci; 2006 Apr;21(2):272-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined expression of Ang-1, Ang-2, and their common receptor Tie2 mRNAs and proteins in gastric cancers using in situ hybridization and immunohistochemistry.
  • [MeSH-major] Angiopoietin-1 / genetics. Angiopoietin-1 / metabolism. Angiopoietin-2 / genetics. Angiopoietin-2 / metabolism. Receptor, TIE-2 / genetics. Receptor, TIE-2 / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / blood supply. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Oct 15;86(8):1455-62 [10526273.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1154-60 [11027428.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1255-9 [11245414.001]
  • [Cites] Pathol Res Pract. 2001;197(2):101-7 [11261813.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2145-53 [11280779.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):918-27 [11309342.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5217-20 [11326698.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5736-40 [11479209.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):651-9 [11485923.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6248-54 [11507079.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):6-15 [11668472.001]
  • [Cites] Leuk Res. 2002 Feb;26(2):163-8 [11755466.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7124-9 [12460935.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):552-7 [12808060.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):168-75 [14757432.001]
  • [Cites] Histopathology. 2004 Mar;44(3):232-9 [14987226.001]
  • [Cites] J Hepatol. 2004 May;40(5):799-807 [15094228.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1557-70 [15509526.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):598-603 [1311287.001]
  • [Cites] Oncogene. 1993 May;8(5):1293-301 [8386827.001]
  • [Cites] Growth Factors. 1993;9(2):99-105 [8217221.001]
  • [Cites] J Pathol. 1996 Jul;179(3):232-7 [8774475.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1161-9 [8980223.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1171-80 [8980224.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):545-50 [9355979.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):594-9 [9778629.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • (PMID = 16614513.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC2734003
  •  go-up   go-down


54. Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, Nunomura M, Fukushima N, Yagyuu T, Nakamine H, Akiyama F, Hoshi K, Matsue K, Hatake K, Oshimi K: Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood; 2010 Dec 16;116(25):5631-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 10 cases of unrecognized self-limited natural killer-cell proliferation in the stomach, designated as lymphomatoid gastropathy (LyGa).
  • Analysis of the 16 specimens biopsied from 10 patients led to a diagnosis of lymphoma or suspected lymphoma in 11 specimens, gastritis for 1 specimen, adenocarcinoma for 1 specimen, and LyGa or suspected LyGa for 3 specimens.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Stomach Diseases / pathology
  • [MeSH-minor] Aged. Blotting, Western. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / genetics. Epstein-Barr Virus Infections / metabolism. Female. Flow Cytometry. Gene Rearrangement. Herpesvirus 4, Human / genetics. Humans. Immunoenzyme Techniques. Immunophenotyping. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Receptors, Antigen, T-Cell, gamma-delta / genetics. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20829373.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


55. Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ: Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec (Hoboken); 2009 Aug;292(8):1114-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridization was used to detect the expression of HGF and bFGF mRNAs, and immunohistochemistry was used to detect CD34 in 105 gastric cancer tissues and in 20 normal control tissues.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Fibroblast Growth Factor 2 / biosynthesis. Hepatocyte Growth Factor / biosynthesis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Antigens, CD34 / metabolism. Endothelial Cells / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Neovascularization, Pathologic. Prognosis. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19533745.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 103107-01-3 / Fibroblast Growth Factor 2; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


56. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


57. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol; 2006 Oct 20;24(30):4922-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally.
  • No somatic mutations of the EGFR exons 18, 19, or 21 were detected and there was no gross amplification of EGFR by fluorescence in situ hybridization.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):910; author reply 911 [17327617.001]
  • [ErratumIn] J Clin Oncol. 2007 Jun 1;25(16):2334
  • (PMID = 17050876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


58. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet; 2009 Nov;126(5):615-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Molecular Biology / methods. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Cadherins / genetics. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Environment. Helicobacter Infections / complications. Helicobacter pylori. Humans. Interleukin-1beta / genetics. Precancerous Conditions / epidemiology. Precancerous Conditions / etiology. Precancerous Conditions / genetics. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Science. 1999 Apr 23;284(5414):651-4 [10213689.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1319-29 [10348815.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2373-9 [10483994.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8492-5 [15574751.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2354-66 [15735748.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1618-23 [17582605.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Am J Gastroenterol. 2007 Sep;102(9):1878-92 [17640324.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2013-8 [17690113.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):832-9 [17568183.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4887-94 [17971584.001]
  • [Cites] J Pathol. 2008 Nov;216(3):295-306 [18788075.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2397-403 [18755583.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):408-19 [18977329.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1704-11 [18941457.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):465-77 [16237216.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10912-20 [16322238.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):643-9 [16247479.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):21-33 [16501831.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):564-72 [16474375.001]
  • [Cites] Mod Pathol. 2006 May;19(5):675-83 [16528374.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1975-84 [16762620.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):246-58 [16831607.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):406-15 [16832408.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1558-66 [16646055.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Gut. 2006 Nov;55(11):1532-3 [17047103.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2250-7 [16774936.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1643-51 [17071588.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):195-200 [18414189.001]
  • [Cites] Mod Pathol. 2008 May;21(5):544-52 [18246045.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2909-17 [18483357.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):685-90 [18311113.001]
  • [Cites] J Hum Genet. 2008;53(6):479-89 [18350251.001]
  • [Cites] JAMA. 2008 May 28;299(20):2423-36 [18505952.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):730-40 [18488030.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):799-809 [18391748.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):925-32 [18440592.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2876-82 [18539967.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2655-63 [18442100.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):490-6 [18396115.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4623-30 [18559507.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):873-80 [10593993.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):36-47 [10611152.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):403-11 [10719371.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] BMJ. 2000 Jun 17;320(7250):1642-6 [10856067.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Cell. 2001 May 4;105(3):369-77 [11348593.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1348-53 [11729114.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48693-701 [11668179.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):159-64 [9892201.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1267; author reply 1268 [18395110.001]
  • [Cites] Future Oncol. 2008 Apr;4(2):229-39 [18407736.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):774-80 [18342503.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1443-51 [18319718.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):274-87 [19013893.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):58-64 [18755497.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):7047-54 [19029944.001]
  • [Cites] Int J Epidemiol. 2008 Dec;37(6):1316-25 [18641418.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2385-93 [18775915.001]
  • [Cites] Am J Epidemiol. 2008 Dec 15;168(12):1409-15 [18945691.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):434-9 [18821580.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):291-8 [19118057.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S161-6 [19120891.001]
  • [Cites] Oncogene. 2008 Jul 10;27(30):4255-60 [18427545.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):392-7 [18675689.001]
  • [Cites] Future Oncol. 2008 Aug;4(4):553-9 [18684065.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1175-81 [18637055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1997-2001 [18708389.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1360-9 [18614201.001]
  • [Cites] J Clin Gastroenterol. 2008 Sep;42(8):910-5 [18645534.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] Cancer. 2008 Sep 1;113(5 Suppl):1225-33 [18720378.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7025-34 [18757416.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):827 [18770893.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2402-8 [18768510.001]
  • [Cites] Helicobacter. 2008 Oct;13 Suppl 1:28-34 [18783519.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):249-55 [18688641.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):593-6 [2847662.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6605-9 [2573419.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):689-96 [11875002.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):331-41 [12044009.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):470-9 [12051735.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G767-77 [12181193.001]
  • [Cites] Nat Med. 2002 Sep;8(9):1011-7 [12195435.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):219-31 [12353264.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1406; author reply 1406-7 [12360507.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):888-91 [12373604.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Histopathology. 2003 Feb;42(2):128-36 [12558744.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1408-19 [12730880.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):606-12 [14696128.001]
  • [Cites] Gut. 2004 Feb;53(2):195-200 [14724149.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1976-83 [15188375.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Oncogene. 1988 Mar;2(3):283-7 [3281095.001]
  • [Cites] Int J Cancer. 1996 Feb 20;69(1):38-43 [8600057.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):382-7 [8775994.001]
  • [Cites] Cancer Lett. 1997 Jan 30;112(2):161-6 [9066723.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Gut. 1998 Feb;42(2):300-3 [9536959.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):410-2 [9708215.001]
  • [Cites] Eur Surg Res. 1989;21(6):313-8 [2633929.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Gut. 1992 Jan;33(1):16-20 [1740271.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5853-5 [8261393.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] Gut. 1993 Aug;34(8):1038-41 [8174949.001]
  • [Cites] Scand J Gastroenterol. 1994 May;29(5):425-9 [8036458.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240 [7715070.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Tumour Biol. 2008;29(6):343-50 [19023234.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):160-5 [18669867.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):236-46 [18996125.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):71-7 [19015200.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Eur J Cancer. 2009 Feb;45(3):461-9 [19081245.001]
  • [Cites] Scand J Gastroenterol. 2009;44(3):339-45 [19031173.001]
  • [Cites] Cancer Sci. 2009 Mar;100(3):413-8 [19154407.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2050-6 [19223545.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):500-5 [19147860.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2677-82 [19170207.001]
  • [Cites] Hum Mol Genet. 2009 May 1;18(9):1545-55 [19168852.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):2995-3002 [19383819.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jun;21(6):630-5 [19295440.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):769-77 [19269014.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2137-48 [19269290.001]
  • [Cites] Forum Nutr. 2007;60:91-6 [17684404.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2360-72 [17545690.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1855-61 [17505514.001]
  • [Cites] Gut. 2007 Jul;56(7):1023 [17566037.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] J Pathol. 2006 Dec;210(4):398-404 [16981245.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):936-46 [17128210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2427-34 [17164366.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):60-9 [17200707.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1330-5 [17187359.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):15-28 [17311530.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Nat Med. 2007 Apr;13(4):470-6 [17401375.001]
  • [Cites] Nat Genet. 2007 May;39(5):605-13 [17450141.001]
  • [Cites] Virchows Arch. 2007 May;450(5):519-27 [17429689.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10181-9 [17974958.001]
  • [Cites] Helicobacter. 2007 Nov;12 Suppl 2:39-44 [17991175.001]
  • [Cites] Gut. 2007 Dec;56(12):1665-70 [17698860.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1989-98 [18054570.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):7-14 [17971340.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):25-30 [17513507.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):234-43 [18176605.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):244-52 [18176606.001]
  • [Cites] BMC Cancer. 2007;7:206 [17996038.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):110-4 [18206535.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):707-14 [18245470.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):500-10 [18242216.001]
  • [Cites] J Gastroenterol. 2008;43(2):115-23 [18306985.001]
  • [Cites] Am J Clin Pathol. 2008 Apr;129(4):613-21 [18343789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4358-63 [18332421.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Cancer Sci. 2008 May;99(5):836-42 [18294278.001]
  • (PMID = 19657673.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / Interleukin-1beta
  • [Number-of-references] 179
  • [Other-IDs] NLM/ PMC2771140
  •  go-up   go-down


59. Alipov G, Nakayama T, Nakashima M, Wen CY, Niino D, Kondo H, Pruglo Y, Sekine I: Epstein-Barr virus-associated gastric carcinoma in Kazakhstan. World J Gastroenterol; 2005 Jan 7;11(1):27-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In situ hybridization (ISH) of EBV-encoded small RNA-1 (EBER-1) was used to identify the presence of EBER-1 signal in 139 formalin-fixed and paraffin-embedded GC tissues from Kazakhstan.
  • [MeSH-major] Adenocarcinoma, Mucinous / ethnology. Carcinoma, Signet Ring Cell / ethnology. Epstein-Barr Virus Infections / ethnology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609391.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC4205378
  •  go-up   go-down


60. Omori Y, Nakayama F, Li D, Kanemitsu K, Semba S, Ito A, Yokozaki H: Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma. Cancer Sci; 2009 Mar;100(3):413-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In formalin-fixed and paraffin-embedded sections of the high frequency of microsatellite instability (MSI-H) and non-MSI-H gastric carcinomas, there was no difference in telomere length monitored by telomere intensity ratio using telomere-fluorescent in situ hybridization.
  • Conversely, the number of the alternative lengthening of telomeres-associated promyelocytic leukemia bodies (APBs) detected by combined promyelocytic leukemia immunofluorescence and telomere-fluorescent in situ hybridization was statistically higher (57%) in the MSI-H gastric carcinomas compared to that in non-MSI-H gastric carcinomas (19%, P = 0.026).
  • These results suggest that alternative lengthening of telomeres-mediated telomere maintenance plays an important role for microsatellite instability-mediated stomach carcinogenesis, as well as the telomerase ribonucleoprotein complex, although the incidence of MSI-H is low.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Mismatch Repair. Microsatellite Instability. Stomach Neoplasms / genetics. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154407.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


61. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


62. Lo YC, Yang YC, Wu IC, Kuo FC, Liu CM, Wang HW, Kuo CH, Wu JY, Wu DC: Capsaicin-induced cell death in a human gastric adenocarcinoma cell line. World J Gastroenterol; 2005 Oct 28;11(40):6254-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsaicin-induced cell death in a human gastric adenocarcinoma cell line.
  • Cell death induced by the binding of capsaicin was examined in a human gastric adenocarcinoma cell line (AGS cells).
  • [MeSH-major] Adenocarcinoma. Capsaicin / pharmacology. Cell Death / drug effects. Stomach Neoplasms
  • [MeSH-minor] Cell Line, Tumor. DNA Fragmentation. Humans. In Situ Nick-End Labeling. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419151.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ PMC4320326
  •  go-up   go-down


63. Blanchette J, Peppas NA: Oral chemotherapeutic delivery: design and cellular response. Ann Biomed Eng; 2005 Feb;33(2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This system is based on hydrophilic polymer carriers to deliver therapeutic agents to the upper region of the small intestine in response to the pH increase when passing from the stomach.
  • Bleomycin was added prior to polymerization to allow in situ polymerization loading.
  • Release studies were carried out in conditions to model the environment of the stomach and small intestine.
  • The potential cytotoxicity of bleomycin on the small intestine was investigated with the use of Caco-2 cells (human colon adenocarcinoma).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771268.001).
  • [ISSN] 0090-6964
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB-000246
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coated Materials, Biocompatible; 0 / Delayed-Action Preparations; 11056-06-7 / Bleomycin; 30IQX730WE / Polyethylene Glycols; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


64. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Siersema PD, van Dekken H: High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res; 2007;118(2-4):130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls.
  • Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology. Nucleic Acid Conformation. Stomach Neoplasms / genetics
  • [MeSH-minor] Disease Progression. Humans. In Situ Hybridization, Fluorescence. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000363.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


65. Hirano N, Tsukamoto T, Mizoshita T, Koriyama C, Akiba S, Campos F, Carrasquilla G, Carrascal E, Cao X, Toyoda T, Ban H, Miki K, Tatematsu M: Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers. Histol Histopathol; 2007 06;22(6):641-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down regulation of gastric and intestinal phenotypic expression in Epstein-Barr virus-associated stomach cancers.
  • AIMS: We have previously demonstrated the importance of gastric and intestinal phenotypic expression for stomach carcinogenesis.
  • In this study, we focused on Epstein-Barr virus (EBV)-associated stomach cancers, with special attention to Cdx2.
  • METHODS AND RESULTS: We evaluated the expression of gastric and intestinal phenotypic markers by immunohistochemistry in 35 EBV-positive [EBV (+)] and 75 EBV-negative [EBV (-)] stomach cancers in Colombia.
  • The expression of Cdx2 and MUC2 was also found to be significantly lower in EBV (+) than in EBV (-) stomach cancers (P=0.0001; P<0.0001).
  • CONCLUSIONS: EBV (+) stomach cancers are characterized by low expression of intestinal phenotype markers, including Cdx2, and only occasional gastric phenotypic expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Biomarkers, Tumor / analysis. Epstein-Barr Virus Infections / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] CDX2 Transcription Factor. Down-Regulation. Female. Herpesvirus 4, Human. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Mucin-2. Mucins / metabolism. Phenotype. RNA, Viral / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357094.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Epstein-Barr virus encoded RNA 1; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / RNA, Viral
  •  go-up   go-down


66. Aurello P, Rossi S, D'Angelo F, Nigri G, Cicchini C, Ciardi A, Coluccia P, Ercolani G, Cescon M, Cucchetti A, Ravaioli M, Del Gaudio M, Ramacciato G: [Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer]. Chir Ital; 2007 Jul-Aug;59(4):435-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Apoptosis. Biomarkers, Tumor / analysis. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Transforming Growth Factor alpha / analysis. Vascular Endothelial Growth Factors / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor C / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966762.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor alpha; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


67. Assumpção PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Demachki S, Smith Mde A, Burbano RR: Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet; 2006 Aug;169(1):45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma.
  • In northern Brazil, the state of Pará shows a high incidence of this disease and the capital ranks among cities with the highest incidence of stomach cancer in the world.
  • To evaluate chromosomal aberrations implicated in gastric carcinogenesis, we analyzed 16 samples of gastric adenocarcinoma by fluorescence in situ hybridization using a chromosome 8 alpha-satellite probe and by direct chromosomal analysis techniques.
  • There was no significant difference between chromosome 8 ploidy and localization, stage, or histological type of adenocarcinoma in our sample.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 8. In Situ Hybridization, Fluorescence. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875936.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT: Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol; 2010;3:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen.
  • Biopsy of gastric ulcer showed moderately differentiated adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Acta Oncol. 2010 Nov;49(8):1246-52 [20429725.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:49-58 [16368871.001]
  • [Cites] N Engl J Med. 2006 Feb 23;354(8):789-90 [16495390.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2012-8 [18381939.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Hematol Oncol. 2010;3:11 [20331897.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • (PMID = 20828403.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2944145
  •  go-up   go-down


69. Zhang L, Zhao ZS, Ru GQ, Ma J: Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol; 2006 Jul 7;12(25):3970-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In situ hybridization and immuno-histochemistry techniques were used to study the expressions of uPA mRNA, uPAR mRNA, VEGF and CD34 protein in 105 gastric carcinoma specimens.
  • [MeSH-major] Adenocarcinoma / metabolism. Neovascularization, Pathologic / metabolism. Receptors, Cell Surface / metabolism. Stomach Neoplasms / metabolism. Urokinase-Type Plasminogen Activator / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Microcirculation / metabolism. Microcirculation / pathology. Middle Aged. RNA, Messenger / metabolism. Receptors, Urokinase Plasminogen Activator. Stomach / blood supply. Stomach / metabolism. Stomach / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 May 15;56(10):2428-33 [8625323.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):179-86 [9583734.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):973-7 [9615749.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Sep;13(9):936-44 [9794194.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):495-504 [10066377.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):869-74 [10340907.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Nov;26(11):673-7 [15777506.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Cell Biol. 2001 Feb 19;152(4):777-84 [11266468.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6511-6 [11522648.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1784-92 [11557572.001]
  • [Cites] Clin Exp Metastasis. 2002;19(6):527-34 [12405290.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):43-9 [12708473.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4648-55 [12907645.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2866-9 [14669355.001]
  • [Cites] Oncology. 2004;66(3):210-7 [15218312.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1309-12 [2479987.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6827-9 [2119883.001]
  • [Cites] J Biol Chem. 1991 Jul 5;266(19):12752-8 [1829461.001]
  • [Cites] J Cell Physiol. 1992 Feb;150(2):258-63 [1734031.001]
  • [Cites] FEBS Lett. 1993 May 3;322(1):37-40 [8387028.001]
  • [Cites] FEBS Lett. 1994 Apr 25;343(2):103-6 [8168613.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9709-16 [7730348.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]
  • [Cites] Clin Exp Metastasis. 1998 Jan;16(1):62-73 [9502078.001]
  • (PMID = 16810742.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ PMC4087704
  •  go-up   go-down


70. Ribeiro HF, Alcântara DF, Matos LA, Sousa JM, Leal MF, Smith MA, Burbano RR, Bahia MO: Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line. Braz J Med Biol Res; 2010 Aug;43(8):717-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study characterized cytogenetically PG-100, the first commercially available gastric cancer cell line derived from a Brazilian patient who had a gastric adenocarcinoma, using GTG banding and fluorescent in situ hybridization to determine MYC amplification.
  • Eighty-six percent of 200 cells analyzed by fluorescent in situ hybridization presented MYC overexpression.


71. von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M: No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog; 2006 May;45(5):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the prevalence of EBER expression (EBV-encoded small RNAs) in a series of small bowel adenocarcinomas (n=56) utilizing RNA in situ hybridization (EBER-RISH).
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Intestinal Neoplasms / virology. Intestine, Small / virology. Stomach Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493667.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


72. Calcagno DQ, Guimarães AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpção PP, De Arruda Cardoso Smith M, Burbano RR: MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res; 2009 Jul;29(7):2479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC insertions in diffuse-type gastric adenocarcinoma.
  • MATERIALS AND METHODS: MYC copy number and its insertion, as well as the chromosomes in which MYC was inserted, were evaluated by fluorescence in situ hybridization assay in interphase and metaphase cells of 12 diffuse-type gastric cancer samples.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 8. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Interphase. Metaphase. Middle Aged. Trisomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596917.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


73. Wang GR, Zheng Y, Che XM, Wang XQ, Wang XW, Pan CE, He WX: [Expression of heparin-binding epidermal growth factor-like growth factor in patients with gastric carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):44-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of HB-EGF protein and mRNA in normal gastric tissues, metaplasic intestinal mucosa, early-stage gastric cancer and advanced-stage gastric cancer tissues were detected by immunohistochemistry and in situ hybridization.
  • [MeSH-major] Adenocarcinoma / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218109.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  •  go-up   go-down


74. Yoshiwara E, Koriyama C, Akiba S, Itoh T, Minakami Y, Chirinos JL, Watanabe J, Takano J, Miyagui J, Hidalgo H, Chacon P, Linares V, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma in Lima, Peru. J Exp Clin Cancer Res; 2005 Mar;24(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) was identified by the in situ hybridization (ISH) technique to detect EBV-encoded small RNA (EBER) in gastric tissue.
  • Other clinicopathological features of EBVaGC in Peru were similar to those found in literature: EBVaGC showed no age dependence, a predominance in the non-antrum part of the stomach, and high frequencies in histological subtypes of moderately differentiated tubular adenocarcinoma and solid poorly differentiated adenocarcinoma.
  • There was a case of well-differentiated adenocarcinoma showing a partial EBER-1-positive staining.
  • In this carcinoma, the tumor in the body (middle third of the stomach) was EBER-1 positive but the tumor in the stomach antrum showed no noticeable EBER-1 ISH staining.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / physiology. Stomach Neoplasms / complications. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943031.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


75. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A: Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol; 2006 Oct;37(10):1333-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
  • In a combined analysis of immunohistochemistry and fluorescence in situ hybridization on 552 formalin-fixed and paraffin-embedded gastric cancer tissues, 38 cases were found to have HER2 amplification.
  • Further examination by fluorescence in situ hybridization revealed amplification of TOP2A in 13 of the 38 cases.
  • Fluorescence in situ hybridization was performed on nuclear imprint specimens obtained from 9 cases using simultaneous probes for TOP2A, HER2, and centromere 17.
  • Although patients having gastric adenocarcinoma with TOP2A amplification could be considered suitable for clinical trials, information involving anthracycline therapy is not firmly understood in regards to the status of TOP2A amplification or protein overexpression.
  • [MeSH-major] Adenocarcinoma / enzymology. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Gene Amplification. Genes, erbB-2. Stomach Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Male. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949920.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


76. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


77. Bizari L, Borim AA, Leite KR, Gonçalves Fde T, Cury PM, Tajara EH, Silva AE: Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet; 2006 Feb;165(1):41-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CCND1 gene amplification (45%) was more prevalent than polysomy (25%) in esophageal carcinoma, but the pattern observed was similar in gastric adenocarcinoma (10% amplification, 15% polysomy).
  • The kappa-statistics revealed a fair agreement in both types of tumors only in overexpression and amplification of the CCND1 gene; the ERBB2 gene showed a fair agreement in amplification and polysomy and the level of protein expression in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclin D1 / genetics. Esophageal Neoplasms / genetics. Gene Amplification. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Helicobacter Infections / epidemiology. Helicobacter pylori. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / genetics. Survival Analysis


78. Aida J, Izumiyama-Shimomura N, Nakamura K, Ishii A, Ishikawa N, Honma N, Kurabayashi R, Kammori M, Poon SS, Arai T, Takubo K: Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method. Hum Pathol; 2007 Aug;38(8):1192-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length variations in 6 mucosal cell types of gastric tissue observed using a novel quantitative fluorescence in situ hybridization method.
  • We developed a novel method for evaluating telomere length in 6 cell types of noncancerous and cancerous mucosal tissues from 11 cases of gastric neoplasm using the quantitative fluorescence in situ hybridization method with telomere and centromere peptide nucleic acid probes.
  • [MeSH-major] Adenocarcinoma / metabolism. Gastric Mucosa / metabolism. In Situ Hybridization, Fluorescence. Stomach Neoplasms / metabolism. Telomere / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588641.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Oligonucleotide Probes; 0 / Peptide Nucleic Acids
  •  go-up   go-down


79. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


80. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


81. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet; 2008 Feb;181(1):31-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma.
  • Early gastric cancer represents approximately 10% of gastric cancer cases in some services of Brazil, which underscores the need for early gastric cancer diagnosis that could lead to better prognosis.
  • To evaluate MYC copy number and its protein expression, we performed fluorescence in situ hybridization and immunohistochemical analyses in five early gastric adenocarcinomas in individuals from northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Brazil. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262050.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Haveri H, Westerholm-Ormio M, Lindfors K, Mäki M, Savilahti E, Andersson LC, Heikinheimo M: Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol; 2008;8:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Samples of normal and neoplastic gastrointestinal tract from children and adults were subjected to RNA in situ hybridization with 33P labelled probes and immunohistochemistry, using an avidin-biotin immunoperoxidase system.
  • Both factors were also present in Barrett's esophagus and metaplasia of the stomach.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colonic Neoplasms / genetics. GATA4 Transcription Factor / metabolism. GATA6 Transcription Factor / metabolism. Gastric Mucosa / metabolism. Rectal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1061-72 [9136933.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1050-4 [16258256.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G297-306 [16603485.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9060-70 [16940177.001]
  • [Cites] Dev Biol. 2002 Jan 1;241(1):34-46 [11784093.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):279-89 [11864602.001]
  • [Cites] Genes Dev. 2002 Apr 1;16(7):784-9 [11937486.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 7;1576(1-2):198-202 [12031502.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3136-43 [12130579.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 29;1490(3):324-32 [10684977.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):184-8 [10942535.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3476-83 [10999851.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):699-704 [11029406.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G58-67 [11123198.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1321-57 [11578958.001]
  • [Cites] FEBS Lett. 1997 May 19;408(2):121-3 [9187350.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):G314-24 [9486185.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2901-11 [9566909.001]
  • [Cites] Development. 1998 Dec;125(24):4909-17 [9811575.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Front Biosci. 1999 Mar 15;4:D286-98 [10077541.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(2):71-6 [10190312.001]
  • [Cites] Circ Res. 1999 Apr 2;84(6):647-54 [10189352.001]
  • [Cites] Mol Med. 1999 Jul;5(7):490-501 [10449810.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):952-60 [15541382.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7917-24 [15585625.001]
  • [Cites] J Cell Physiol. 2005 Apr;203(1):15-26 [15389642.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):15-24 [15703995.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] J Pathol. 2002 Aug;197(5):582-8 [12210076.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):368-77 [12527808.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4705-12 [12468531.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8429-39 [14612389.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):408-12 [15144399.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G899-909 [15178553.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1086-99 [14715527.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10876-80 [8248184.001]
  • [Cites] Dev Biol. 1994 Aug;164(2):361-73 [8045339.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1559-67 [9136834.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • (PMID = 18405344.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA6 Transcription Factor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2323380
  •  go-up   go-down


83. Rice TW, Rusch VW, Ishwaran H, Blackstone EH, Worldwide Esophageal Cancer Collaboration: Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer; 2010 Aug 15;116(16):3763-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) stage groupings for esophageal cancer have not been data driven or harmonized with stomach cancer.
  • Stage groupings for stage I and II adenocarcinoma were based on pT, pN, and histologic grade; and groupings for squamous cell carcinoma were based on pT, pN, histologic grade, and location.
  • Stage 0 and stage IV, by definition, were categorized as tumor in situ (Tis) (high-grade dysplasia) and pM1, respectively.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564099.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Maqani N, Belkhiri A, Moskaluk C, Knuutila S, Dar AA, El-Rifai W: Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res; 2006 Jul;4(7):449-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA amplification at 17q is frequently detected in upper gastrointestinal adenocarcinomas (UGC; stomach and esophagus).
  • In this study, we did fluorescence in situ hybridization on a tissue microarray that contained 304 UGCs and 89 normal stomach samples using a approximately 168-kb BAC clone (CTD-2019C10) that maps to 17q12-q21.1.
  • Adenocarcinomas of gastroesophageal junction and lower esophagus had the highest frequency of amplification (45%) compared with stomach tumors (27%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 17 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Female. Gene Amplification. Gene Dosage. Humans. In Situ Hybridization, Fluorescence / methods. Male. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods


85. Callacondo D, Ganoza-Salas A, Anicama-Lima W, Quispe-Mauricio A, Longacre TA: Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis: a case report and review of literature. Hum Pathol; 2009 Oct;40(10):1494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the stomach with paraneoplastic leukocytosis: a case report and review of literature.
  • Apparently pure, primary squamous cell carcinoma of the stomach is exceedingly rare.
  • Immunohistochemical and in situ hybridization studies for human papillomavirus and Epstein-Barr virus were negative.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Leukocytosis / pathology. Paraneoplastic Syndromes / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged, 80 and over. Diabetes Mellitus, Type 2 / complications. Humans. Hypertension / complications. Immunohistochemistry. In Situ Hybridization. Male. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Feb;41(2):307. Callacondo-Riva, David [corrected to Callacondo, David]
  • (PMID = 19467693.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Kim B, Byun SJ, Kim YA, Kim JE, Lee BL, Kim WH, Chang MS: Cell cycle regulators, APC/beta-catenin, NF-kappaB and Epstein-Barr virus in gastric carcinomas. Pathology; 2010 Jan;42(1):58-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated cell cycle regulators (p53, p21, Rb), APC, beta-catenin and NF-kappaB using immunohistochemistry and EBV using in situ hybridisation for EBV encoded small RNAs in 117 cases of gastric carcinoma.
  • EBV positive gastric carcinomas were located in the upper third of the stomach, and more were of the diffuse or mixed types than the EBV negative group (p < 0.05).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / metabolism. Stomach Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / virology. Adenomatous Polyposis Coli Protein / metabolism. Adult. Aged. Aged, 80 and over. Cell Cycle Proteins / metabolism. Comorbidity. Female. Humans. In Situ Hybridization. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. NF-kappa B / metabolism. Neoplasm Staging. Survival Rate. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025482.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / NF-kappa B; 0 / beta Catenin
  •  go-up   go-down


87. Wu CS, Chen MF, Lee IL, Tung SY: Predictive role of nuclear factor-kappaB activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J Clin Gastroenterol; 2007 Nov-Dec;41(10):894-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also performed electrophoretic mobility gel shift assay, real-time reverse transcription polymerase chain reaction, and enzyme-linked immunosorbent assay to evaluate the responses of AGS (a gastric adenocarcinoma epithelial cell line) human gastric cancer cells subsequent to H. pylori infection or CAPE treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Caffeic Acids / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / microbiology. Helicobacter pylori / pathogenicity. NF-kappa B / metabolism. Phenylethyl Alcohol / analogs & derivatives. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / microbiology. Carcinoma in Situ / pathology. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Nucleus / microbiology. Cell Survival. Helicobacter Infections / microbiology. Humans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. 2-PHENYLETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2007 Nov-Dec;41(10):871-3 [18090154.001]
  • (PMID = 18090157.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caffeic Acids; 0 / NF-kappa B; G960R9S5SK / caffeic acid phenethyl ester; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


88. Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y: The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol; 2010 Jan;41(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the role of Reg IV in gastric carcinogenesis and subsequent progression, we examined its expression by immunohistochemistry and in situ hybridization on tissue microarray containing gastric carcinoma, adjacent nonneoplastic mucosa, adenoma, intestinal metaplasia, or gastritis.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA, Neoplasm / analysis. Female. Gastric Mucosa / metabolism. Gastritis / genetics. Gastritis / metabolism. Gastritis / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions. Sequence Analysis, DNA. Tissue Array Analysis


89. Trimeche M, Ksiâa F, Ziadi S, Mestiri S, Hachana M, Gacem RB, Sriha B, Korbi S: Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Tunisia. Eur J Gastroenterol Hepatol; 2009 Sep;21(9):1001-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ninety-six nonselected GC cases (male/female ratio 1.7/1, mean age 60.9 years, range: 20-88 years) were evaluated for the presence of EBV by polymerase chain reaction as well as by in-situ hybridization for EBV-encoded small RNAs (EBERs) and immunohistochemistry for LMP-1 and EBNA-2 expression.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491698.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


90. Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG, Zhao ZS: Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken); 2010 Dec;293(12):2012-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ hybridization of MMP-9 mRNA and immunohistochemistry of VEGF and CD34 proteins were performed on surgical specimens of gastric cancers from 118 patients compared with 20 nonmalignant gastric mucosae.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 9 / metabolism. Stomach Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21089052.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


91. Wang GS, Wang MW, Wu BY, Yang XY, Wang WH, You WD: LINE-1 family member GCRG123 gene is up-regulated in human gastric signet-ring cell carcinoma. World J Gastroenterol; 2008 Feb 7;14(5):758-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In situ hybridization was used to explore the GCRG123 expression pattern in paraffin-embedded gastric tissues, including 15 cases of signet-ring cell carcinoma, 15 of intestinal-type adenocarcinoma, and 15 of normal gastric mucosa.
  • Northern blotting was used to analyze the differences in GCRG123 expression between stomach signet-ring cell carcinoma and intestinal-type adenocarcinoma tissues.
  • RESULTS: The in situ hybridization signal appeared as blue precipitates restricted to the cytoplasm.
  • Low GCRG123 expression was observed in gastric intestinal-type adenocarcinoma and normal gastric glands.
  • Northern blotting revealed that GCRG123 was up-regulated in signet-ring cell carcinoma tissue but down-regulated in intestinal-type adenocarcinoma tissue.
  • [MeSH-major] Carcinoma, Signet Ring Cell / genetics. Gene Expression Regulation, Neoplastic. Lamins / genetics. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006;34(5):1512-21 [16554555.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3189-98 [17589897.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8036-41 [16698926.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:211-50 [16909913.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2485-92 [17029617.001]
  • [Cites] J Pathol. 2007 Feb;211(3):269-77 [17139617.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):306-9 [11007163.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):926-35 [11371580.001]
  • [Cites] Annu Rev Genet. 2001;35:501-38 [11700292.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Apr;20(2):119-22 [12673572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5280-5 [12682288.001]
  • [Cites] Curr Opin Genet Dev. 2003 Dec;13(6):651-8 [14638329.001]
  • [Cites] J Inherit Metab Dis. 2004;27(3):319-30 [15190191.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Gan No Rinsho. 1969 Jul;15(7):627-47 [5817661.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Nature. 1980 Apr 17;284(5757):604-7 [7366731.001]
  • [Cites] Nucleic Acids Res. 1988 Nov 25;16(22):10881-90 [2849754.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Scand J Gastroenterol Suppl. 1991;180:160-4 [2042032.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):643-5 [1310068.001]
  • [Cites] Histochemistry. 1992 Nov;98(4):217-28 [1459861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11533-7 [8265584.001]
  • [Cites] Gene. 1993 Dec 15;135(1-2):183-8 [8276257.001]
  • [Cites] Diagn Mol Pathol. 1992 Jun;1(2):142-50 [1342960.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):424-6 [7640228.001]
  • [Cites] Gene. 1996 Oct 17;176(1-2):39-44 [8918229.001]
  • [Cites] Cell. 1996 Nov 29;87(5):905-16 [8945517.001]
  • [Cites] Cell. 1996 Nov 29;87(5):917-27 [8945518.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Mar;18(3):232-9 [9071577.001]
  • [Cites] EMBO J. 1997 Oct 1;16(19):6034-43 [9312060.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 30;253(3):566-70 [9918768.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:227-34 [10022258.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1312-21 [10424731.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3923-31 [15806170.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):903-10 [15959507.001]
  • [Cites] Oncol Res. 2005;15(5):257-64 [16261845.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):1-10 [16175572.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Oncogene. 2007 Apr 12;26(17):2518-24 [17043645.001]
  • [Cites] Hum Mol Genet. 2007 Jul 1;16(13):1569-77 [17468180.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):416-25 [16616344.001]
  • (PMID = 18205268.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF454554
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GCRG123 protein, human; 0 / Lamins
  • [Other-IDs] NLM/ PMC2684005
  •  go-up   go-down


92. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


93. De Caro G, Pagano N, Malesci A, Hervoso C, Danese S, Romeo F, Delconte G, Repici A: Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 72-year-old woman underwent gastric endoscopic mucosal resection with a cap-fitted endoscope for an adenocarcinoma in situ.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / adverse effects. Neoplasm Recurrence, Local / surgery. Stomach Diseases / etiology. Stomach Neoplasms / surgery. Surgical Instruments
  • [MeSH-minor] Aged. Cicatrix / pathology. Cicatrix / surgery. Female. Humans. Iatrogenic Disease. Stomach / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620913.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, Teng LS, Wang M, Wu FS, Luo B: Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. World J Gastroenterol; 2006 Mar 7;12(9):1356-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • AIM: To study the apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
  • Fas/FasL,PD-ECGF and PCNA were examined by immunohistochemistry and apoptotic tumor cells were detected by in situ TUNEL method.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis / drug effects. Floxuridine / pharmacology. Floxuridine / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4363-7 [10650777.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):31-6 [10963377.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7826-37 [11003676.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Sep;27(10):1521-6 [11015996.001]
  • [Cites] Cell Res. 2000 Sep;10(3):233-42 [11032175.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jan;127(1):20-6 [11206267.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):103-11 [11295293.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1157-62 [11351245.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):222-4 [11778236.001]
  • [Cites] Cell Death Differ. 2002 Apr;9(4):431-8 [11965496.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jan;24(1):4-8 [11977635.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):882-6 [12064013.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):360-3 [12408764.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1628-33 [8608554.001]
  • [Cites] J Surg Oncol. 1997 Jun;65(2):106-10 [9209521.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Oct;24(13):1947-52 [9350241.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Feb;25(3):359-64 [9492829.001]
  • [Cites] Mol Pharmacol. 1998 May;53(5):819-26 [9584207.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Feb;26(3):321-7 [10065095.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1334-42 [10081495.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1145-50 [10098749.001]
  • [Cites] Oncology. 1999 Apr;56(3):215-22 [10202277.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1911-6 [10213500.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2607-12 [12529971.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):115-9 [12469155.001]
  • [Cites] World J Gastroenterol. 2003 Mar;9(3):442-5 [12632493.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):660-4 [12679905.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):717-20 [12679918.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Jan;25(1):66-9 [12678992.001]
  • [Cites] Kongressbd Dtsch Ges Chir Kongr. 2002;119:396-7 [12704896.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1800-7 [12771998.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):347-9 [14514381.001]
  • [Cites] Surg Today. 2003;33(11):847-53 [14605957.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):348-51 [14760755.001]
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):484-90 [14966903.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):804-8 [15040021.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):4-9 [15059341.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1233-9 [15138561.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] World J Gastroenterol. 2004 Oct 1;10(19):2911-5 [15334700.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1501-6 [1893349.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44 [8230264.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):509-16 [7676692.001]
  • (PMID = 16552801.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Apoptosis Regulatory Proteins; 0 / FAIM protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Necrosis Factors; 039LU44I5M / Floxuridine; EC 2.4.2.4 / Thymidine Phosphorylase; V1JK16Y2JP / doxifluridine
  • [Other-IDs] NLM/ PMC4124310
  •  go-up   go-down


95. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


96. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer; 2009 Mar 10;100(5):732-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amplification of EGFR gene was analysed using fluorescent in situ hybridisation (FISH).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Gastrectomy. Receptor, Epidermal Growth Factor / genetics. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5635-40 [10697632.001]
  • [Cites] Oncology. 2008;74(1-2):76-83 [18544998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 [10952103.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):761-8 [12014648.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):9-15 [14654896.001]
  • [Cites] Dig Dis Sci. 2004 Jan;49(1):60-4 [14992436.001]
  • [Cites] Eur J Cancer. 2004 May;40(7):939-50 [15093568.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3794-9 [15173087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3230-7 [15310766.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2495-501 [15330204.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2484-94 [15353301.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Cancer Lett. 1996 Nov 29;108(2):281-90 [8973606.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):309-16 [9440758.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1213-6 [10523683.001]
  • [Cites] Chest. 2005 Mar;127(3):978-83 [15764785.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):337-44 [16777480.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):436-48 [16890798.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2435-42 [16894565.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2304-12 [16894566.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1818-25 [16980606.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):504-9 [17322540.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):622-31 [17431415.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4154-63 [17634543.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):139-48 [18207460.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):832-9 [18231104.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3022-9 [18483367.001]
  • [Cites] Lung Cancer. 2008 Jun;60(3):401-7 [18036700.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • (PMID = 19259093.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2653762
  •  go-up